Elena V Preobrazhenskaya1, Ilya V Bizin2, Ekatherina Sh Kuligina1, Alla Yu Shleykina1, Evgeny N Suspitsin1,3, Olga A Zaytseva1, Elena I Anisimova4, Sergey A Laptiev5, Tatiana V Gorodnova1, Alexey M Belyaev1, Evgeny N Imyanitov1,3,5,6, Anna P Sokolenko7,8,9. 1. N.N. Petrov Institute of Oncology, St.-Petersburg, Russia. 2. Peter the Great St.-Petersburg Polytechnic University, St.-Petersburg, Russia. 3. St.-Petersburg State Pediatric Medical University, St.-Petersburg, Russia. 4. Leningrad Regional Oncology Center, St.-Petersburg, Russia. 5. Pavlov First St.-Petersburg State Medical University, St.-Petersburg, Russia. 6. I.I. Mechnikov North-Western Medical University, St.-Petersburg, Russia. 7. N.N. Petrov Institute of Oncology, St.-Petersburg, Russia. annasokolenko@mail.ru. 8. St.-Petersburg State Pediatric Medical University, St.-Petersburg, Russia. annasokolenko@mail.ru. 9. Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, St.-Petersburg, Russia, 197758. annasokolenko@mail.ru.
Abstract
PURPOSE: Large genomic rearrangements (LGRs) constitute a significant share of pathogenic BRCA1 mutations. Multiplex ligation-dependent probe amplification (MLPA) is a leading method for LGR detection; however, it is entirely based on the use of commercial kits, includes relatively time-consuming hybridization step, and is not convenient for large-scale screening of recurrent LGRs. MATERIALS AND METHODS: We developed and validated the droplet digital PCR (ddPCR) assay, which covers the entire coding region of BRCA1 gene and is capable to precisely quantitate the copy number for each exon. RESULTS: 141 breast cancer (BC) patients, who demonstrated evident clinical features of hereditary BC but turned out to be negative for founder BRCA1/2 mutations, were subjected to the LGR analysis. Four patients with LGR were identified, with three cases of exon 8 deletion and one women carrying the deletion of exons 5-7. Excellent concordance with MLPA test was observed. Exon 8 copy number was tested in additional 720 BC and 184 ovarian cancer (OC) high-risk patients, and another four cases with the deletion were revealed; MLPA re-analysis demonstrated that exon 8 loss was a part of a larger genetic alteration in two cases, while the remaining two patients had isolated defect of exon 8. Long-range PCR and next generation sequencing of DNA samples carrying exon 8 deletion revealed two types of recurrent LGRs. CONCLUSION: Droplet digital PCR is a reliable tool for the detection of large genomic rearrangements.
PURPOSE: Large genomic rearrangements (LGRs) constitute a significant share of pathogenic BRCA1 mutations. Multiplex ligation-dependent probe amplification (MLPA) is a leading method for LGR detection; however, it is entirely based on the use of commercial kits, includes relatively time-consuming hybridization step, and is not convenient for large-scale screening of recurrent LGRs. MATERIALS AND METHODS: We developed and validated the droplet digital PCR (ddPCR) assay, which covers the entire coding region of BRCA1 gene and is capable to precisely quantitate the copy number for each exon. RESULTS: 141 breast cancer (BC) patients, who demonstrated evident clinical features of hereditary BC but turned out to be negative for founder BRCA1/2 mutations, were subjected to the LGR analysis. Four patients with LGR were identified, with three cases of exon 8 deletion and one women carrying the deletion of exons 5-7. Excellent concordance with MLPA test was observed. Exon 8 copy number was tested in additional 720 BC and 184 ovarian cancer (OC) high-risk patients, and another four cases with the deletion were revealed; MLPA re-analysis demonstrated that exon 8 loss was a part of a larger genetic alteration in two cases, while the remaining two patients had isolated defect of exon 8. Long-range PCR and next generation sequencing of DNA samples carrying exon 8 deletion revealed two types of recurrent LGRs. CONCLUSION: Droplet digital PCR is a reliable tool for the detection of large genomic rearrangements.
Entities:
Keywords:
BRCA1 mutation; Droplet digital PCR; Large genomic rearrangements